Article
Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.
International journal of cancer - 1 Sept 2009
Mucci Lorelei A, Stark Jennifer R, Figg William D, Schumacher Fredrick, Li Haojie, Abe Miyako, Hennessy Kristen, Stampfer Meir J, Gaziano John Michael, Ma Jing, Kantoff Philip W
Abstract excerpt
Endostatin inhibits endothelial cell proliferation and migration, prerequisites of angiogenesis. A functional missense mutation (D104N) in endostatin was associated with an increased prostate cancer risk in a small study. We undertook a larger, prospective study within the Physicians' Health Study to examine D104N and prostate cancer risk and progression among 544 incident prostate cancer cases (1982-1995) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.